The board of directors of the Company of MicroPort CardioFlow Medtech Corporation announced that, on January 5, 2024, MP CardioAdvent received the approval from the National Medical Products Administration of the People's Republic of China regarding the registration application for AnchorMan left atrial appendage closure system, the self-development product of MP CardioAdvent, which is also the only approved semi-closed type LAAC product in China so far. In addition, it completed the registration application of CE Mark in December 2023. AnchorMan LAAC System comprises a LAA closure and a delivery system, which is applicable for patients with nonvalvular atrial fibrillation with the CHA2DS2-VASC (a stroke risk assessment tool) score 2 and have contraindications in long-term oral anticoagulation therapy or still at risk of stroke after anticoagulation therapy.

The major innovative designs of AnchorMan LAAC System include: the semi-closed structure formed by the 12 "3D folding" units and the frame combines the merits of an open and closed closure device, solving the clinical pain point that the access sheath of the traditional plug-in closure device must deep into the LAA, and achieving stable anchoring, the rounded and soft distal end could reduce damage to the LAA tissue; the dense NiTi alloy frame design allows very tight conformity to the anatomy of LAA and achieves better sealing performance; and two deployment models of advancement and unsheathe are available to provide more options for physicians. In addition, AnchorMan LAAC System is available in six closure device diameters ranging from 20 mm to 35 mm for a larger patient population. The NMPA registration approval of the AnchorMan LAAC System enables the Group to expand its business from heart valves to a new segment in the structural heart disease field with large patient population and fast growth rate, which will further expand the Company's revenue stream and enhance its comprehensive competitiveness.